Dr. Harald Mosler
Dr. Harald Mosler acts as a partner at MOSLER+PARTNER RECHTSANWÄLTE, which was founded in 1982. He was born in Munich and obtained a Law Degree from Ludwig-Maximilians University of Munich, from which he graduated with distinction in 1978. Afterwards, Harald did an internship at the Higher Regional Court Munich. He holds a PhD in European Gambling Law and received the Qualification of Judgeship in 1980. Harald is a member in a number of supervisory and advisory boards. He is also an entrepreneur in Real Estate Development and construction materials. Harald is married since 1979 and has two adult children.
Dr. Frank Mathias
Dr. Frank Mathias is Chief Executive Officer of Rentschler Biotechnologie GmbH since April 2016. Frank Mathias, previously CEO of Medigene AG from 2009 to 2016, possesses over 30 years of relevant experience in leading positions in the pharmaceutical and biotech industry. He holds a PhD in pharmacy in the field of immunology and worked among other companies for Hoechst AG, prior to assuming in 1995 the General Manager position at Servier Deutschland GmbH in Munich. In 2002, he joined Amgen in Munich, where he served as corporate VP and General Manager from 2003 to 2008. In addition, he is Chairman of vfa bio since 2005 which represents the biotech interests within the German Association of Research-Based Pharmaceutical Companies.
Dr. Gerhard Ries
Dr. Gerhard Ries is Managing Partner of LifeCare Partners, a dedicated venture capital and private equity firm in the European healthcare sector. Gerhard has more than 20 years of global pharma industry and venture capital experience as both entrepreneur and investor. He supervised more than 50 investments in life science companies and served on the board of more than 20 companies. Gerhard has a strong scientific and operational background and held various corporate positions at McKinsey, Novartis, Ciba Geigy and Boehringer Mannheim and was co-founder and Managing Partner of BioMedPartners. Gerhard holds a M.S. and a Ph.D. degree in Molecular Biology from the University of Basel as well as a M.Sc. degree in Biotechnology from the Fachhochschule Weihenstephan.
Jean-Paul Prieels, PhD
Jaul-Paul Prieels holds a PhD in Biochemistry from Université Libre de Bruxelles in Belgium. After ten years at university, he started his industrial career at Petrofina in 1983 as Biotechnology Manager and joined GlaxoSmithKline Biologicals in 1987. His responsibilities gradually expanded to lead the vaccine preclinical R&D development activities in Rixensart, Belgium, and he retired as Senior Vice President of Research & Development in 2011. He was instrumental in the development of several commercially available vaccines, such as Rotarix, Cervarix and Synflorix. Today, he is Director at various companies and member of the Scientific Advisory Board of Singapore Bioprocessing Technology Institute and MolMed SPA. He is also a member of the European Vaccine Initiative Board of Stakeholders.
Dr. Wolfgang Schwandner
Dr. Wolfgang Schwandner is a business angel and investor in several health care and life science companies. He is founder of various pharmaceutical and health care companies focusing on generic manufacturing, wholesaling and service, and has more than 20 years of experience in executive positions in the international pharmaceutical industry. He holds a diploma and a PhD degree in Biology from Ludwig-Maximilians-Universität and Technische Universität München. Wolfgang is married, has two daughters and lives near Munich.
Dr. Andreas Rummelt
Dr. Andreas Rummelt is Partner and CEO of InterPharmaLink AG, a Management Consulting firm in Basel, Switzerland. His international career in pharmaceuticals has focused on the areas of manufacturing, quality, technical development and generics and he has served more than twenty years in executive management positions in the industry. From 2004 to 2008, Dr. Rummelt was CEO of Sandoz in Vienna and Holzkirchen. He also served as Group Head of Quality Assurance and Technical Operations at Novartis, a position he held from 2008 until 2010, and he had been a member of the Executive Committee of Novartis from 2006 until his resignation in 2010. Dr. Rummelt is a pharmacist and holds a Ph.D. degree from the University of Erlangen-Nuremberg.